Clinical trial / 2006
Glucosamine and chondroitin sulfate, alone or combined, did not significantly reduce knee osteoarthritis pain overall compared to placebo.
In the GAIT trial, 1,583 patients with symptomatic knee osteoarthritis were randomized to receive 1500 mg glucosamine, 1200 mg chondroitin sulfate, both, 200 mg celecoxib, or placebo daily for 24 weeks. Overall, response rates were not significantly higher than placebo (60.1%) for glucosamine (+3.9 percentage points, P=0.30), chondroitin sulfate (+5.3 percentage points, P=0.17), or the combination (+6.5 percentage points, P=0.09), whereas celecoxib was significantly higher (+10.0 percentage points, P=0.008). In an exploratory subgroup with moderate-to-severe baseline pain, combined therapy had a significantly higher response rate than placebo (79.2% vs. 54.3%, P=0.002).
- Study type
- Multicenter, double-blind, randomized controlled trial
- Who was studied
- 1,583 patients with symptomatic knee osteoarthritis
- What was measured
- 20 percent decrease in knee pain from baseline to week 24
THE PAPER
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. N Engl J Med, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.